

9 January 2024

Treatment of Dermatological Conditions

1. How many patients were treated in the last 4 months (August to November 2023) by the Dermatology department with each of the following products:

• Abrocitinib	5
• Acitretin	<5
• Alitretinoin	<5
• Azathioprine	<5
• Baricitinib	<5
• Ciclosporin	<5
• Dupilumab	153
• Methotrexate	<5
• Mycophenolate mofetil	<5
• Pimecrolimus	<5
• Phototherapy (UVB or PUVA) – for Atopic Dermatitis only	0
• Tacrolimus ointment	<5
• Tralokinumab	<5
• Upadacitinib	24

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

2. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

• Age 6 - 11	11
• Age 12 - 17	25
• Age 18 and above	146